Hikma stock holds steady after a half year update
Published on 08/20/2026 at 10:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Hikma Pharmaceuticals PLC (GB00B128J450) stock traded at 1,652.00 GBX on August 19, 2026, after the latest market snapshot showed 46.68K shares changing hands. The same half year update from August 6, 2026 put revenue at $1.73 billion and earnings per share at $1.02.
Half year numbers
The August 6 update also showed a mixed earnings picture, with reported attributable profit slipping while revenue rose. That combination matters because it keeps attention on margin quality rather than only on top-line growth.
Hikma's year-to-date move stood at +5.08% in the August 19 market snapshot, while the same view showed a five-day change of +1.50%. Against a 1,657.50 GBX close on August 18, the shares remained in a narrow range around the mid-1,600s.
Analyst backdrop
The latest consensus view pointed to an average 12-month target of GBX 2,060 from six analysts, with a high of GBX 2,400 and a low of GBX 1,870. That leaves the stock below the average target by 408.00 GBX, a concrete gap that helps frame sentiment after the half year update.
The broader sector backdrop was mixed as well, with Hikma trading alongside larger London healthcare names in the same market view. For investors, the comparison suggests the stock is being judged on company-specific earnings delivery rather than a broad sector rerating.
Products and pipeline
Hikma's product mix still centers on generic and branded pharmaceuticals, and recent headlines around launches and approvals show why the pipeline remains part of the valuation debate. The business mix matters because the half year numbers alone do not capture how product timing can affect the second half.
More on Hikma stock and company updates.
Hikma stock price
Hikma stock traded at 1,652.00 GBX on August 19, 2026, after a 1,657.50 GBX close on August 18, 2026.
Company facts
Company: Hikma Pharmaceuticals PLC
ISIN: GB00B128J450
Ticker: HIK
Exchange: LSE
Sector / Industry: Healthcare / Pharmaceuticals
Index membership: FTSE 250
Next earnings date: September 8, 2026
